These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8852390)
21. Pharmacokinetics of loratadine in patients with renal insufficiency. Matzke GR; Halstenson CE; Opsahl JA; Hilbert J; Perentesis G; Radwanski E; Zampaglione N J Clin Pharmacol; 1990 Apr; 30(4):364-71. PubMed ID: 2140371 [TBL] [Abstract][Full Text] [Related]
22. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Cheskin LJ; Chami TN; Johnson RE; Jaffe JH Drug Alcohol Depend; 1995 Aug; 39(2):151-4. PubMed ID: 8529534 [TBL] [Abstract][Full Text] [Related]
23. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. Krieter P; Gyaw S; Crystal R; Skolnick P J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694 [TBL] [Abstract][Full Text] [Related]
24. Comparison of potency and duration of action of nalmefene and naloxone. Glass PS; Jhaveri RM; Smith LR Anesth Analg; 1994 Mar; 78(3):536-41. PubMed ID: 8109774 [TBL] [Abstract][Full Text] [Related]
25. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427 [TBL] [Abstract][Full Text] [Related]
27. Nalmefene for elective reversal of procedural sedation in children. Chumpa A; Kaplan RL; Burns MM; Shannon MW Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998 [TBL] [Abstract][Full Text] [Related]
28. Nalmefene: radioimmunoassay for a new opioid antagonist. Dixon R; Hsiao J; Taaffe W; Hahn E; Tuttle R J Pharm Sci; 1984 Nov; 73(11):1645-6. PubMed ID: 6520774 [TBL] [Abstract][Full Text] [Related]
29. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468 [TBL] [Abstract][Full Text] [Related]
30. Prolonged blockade of opioid effect with oral nalmefene. Gal TJ; DiFazio CA; Dixon R Clin Pharmacol Ther; 1986 Nov; 40(5):537-42. PubMed ID: 3533370 [TBL] [Abstract][Full Text] [Related]
31. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans. Li P; Chen X; Dai X; Wen A; Zhang Y; Zhong D J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):479-84. PubMed ID: 17329173 [TBL] [Abstract][Full Text] [Related]
32. Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies. Chou JZ; Albeck H; Kreek MJ J Chromatogr; 1993 Apr; 613(2):359-64. PubMed ID: 8491826 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of cefepime in subjects with renal insufficiency. Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125 [TBL] [Abstract][Full Text] [Related]
34. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure. Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108 [TBL] [Abstract][Full Text] [Related]
35. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807 [TBL] [Abstract][Full Text] [Related]
37. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Joshi GP; Duffy L; Chehade J; Wesevich J; Gajraj N; Johnson ER Anesthesiology; 1999 Apr; 90(4):1007-11. PubMed ID: 10201671 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Aparicio M; Dratwa M; el Esper N; Fillastre JP; Levaltier B; Lins R; Meyrier A; Mignon F; Ryckelynck JP; Sennesael J Am J Cardiol; 1994 Dec; 74(13):43A-50A. PubMed ID: 7998585 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study. Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266 [TBL] [Abstract][Full Text] [Related]
40. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. Dixon R; Gentile J; Hsu HB; Hsiao J; Howes J; Garg D; Weidler D J Clin Pharmacol; 1987 Mar; 27(3):233-9. PubMed ID: 3680580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]